The Effect of GD-iExo-003 in Acute Ischemic Stroke - Trial NCT06138210
Access comprehensive clinical trial information for NCT06138210 through Pure Global AI's free database. This Phase 1 trial is sponsored by Xuanwu Hospital, Beijing and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 29 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
exosomes derived from human induced pluripotent stem cell for injection
Interventional
drug
Sponsor & Location
Xuanwu Hospital, Beijing
Timeline & Enrollment
Phase 1
Jan 30, 2024
Aug 30, 2025
Primary Outcome
Number of participants who experienced dose-limiting Toxicities (DLTs)
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial.
 The objective of this study is evaluating safety and preliminary efficacy of intravenous
 exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic
 stroke.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06138210
Non-Device Trial